Combined resection and RFA in colorectal liver metastases: stratification of long-term outcomes

Journal of Surgical Research

Volumn 206, Issue 1, 2016, Pages 182-189

  Sasaki, Kazunari ^a   Margonis, Georgios A ^a   Andreatos, Nikolaos ^a   Kim, Yuhree ^a   Wilson, Ana ^a   Gani, Faiz ^a   Amini, Neda ^a   Pawlik, Timothy M ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Colorectal cancer liver metastases; Hepatectomy; Radiofrequency ablation; RFA

Indexed keywords

ADULT; AGED; ARTICLE; BIOLOGY; CANCER PROGNOSIS; CLINICAL FEATURE; COLORECTAL LIVER METASTASIS; CONFIDENCE INTERVAL; FEMALE; HAZARD RATIO; HUMAN; LIVER RESECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PATIENT SELECTION; PERIOPERATIVE PERIOD; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RISK FACTOR; TREATMENT OUTCOME; CATHETER ABLATION; COLORECTAL TUMOR; FOLLOW UP; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL ANALYSIS;

ADULT; AGED; CATHETER ABLATION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PATIENT SELECTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84983422692     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2016.06.098     Document Type: Article

References (32)

1. 1 Jemal, A., Bray, F., Center, M.M., et al. Global cancer statistics. CA Cancer J Clin 61 (2011), 69–90.
2. 2 House, M.G., Ito, H., Gönen, M., et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 210 (2010), 744–752 752-5.
3. 3 Kopetz, S., Chang, G.J., Overman, M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27 (2009), 3677–3683.
4. 4 Choti, M.A., Sitzmann, J.V., Tiburi, M.F., et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235 (2002), 759–766.
5. 5 Rees, M., Tekkis, P.P., Welsh, F.K., O'Rourke, T., John, T.G., Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247 (2008), 125–135.
6. 6 Adam, R., Wicherts, D.A., de Haas, R.J., et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?. J Clin Oncol 27 (2009), 1829–1835.
7. 7 Folprecht, G., Gruenberger, T., Bechstein, W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11 (2010), 38–47.
8. 8 Ye, L.C., Liu, T.S., Ren, L., et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 31 (2013), 1931–1938.
9. 9 Wicherts, D.A., Miller, R., de Haas, R.J., et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg 248 (2008), 994–1005.
10. 10 Narita, M., Oussoultzoglou, E., Jaeck, D., et al. Two-stage hepatectomy for multiple bilobar colorectal liver metastases. Br J Surg 98 (2011), 1463–1475.
11. 11 Shindoh, J., Tzeng, C.W., Aloia, T.A., et al. Portal vein embolization improves rate of resection of extensive colorectal liver metastases without worsening survival. Br J Surg 100 (2013), 1777–1783.
12. 12 Gleisner, A.L., Choti, M.A., Assumpcao, L., Nathan, H., Schulick, R.D., Pawlik, T.M., Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 143 (2008), 1204–1212.
13. 13 Kornprat, P., Jarnagin, W.R., DeMatteo, R.P., Fong, Y., Blumgart, L.H., D'Angelica, M., Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer. Arch Surg 142 (2007), 1087–1092.
14. 14 Elias, D., Baton, O., Sideris, L., et al. Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol 90 (2005), 36–42.
15. 15 de Jong, M.C., van Vledder, M.G., Ribero, D., et al. Therapeutic efficacy of combined intraoperative ablation and resection for colorectal liver metastases: an international, multi-institutional analysis. J Gastrointest Surg 15 (2011), 336–344.
16. 16 Abbott, D.E., Sohn, V.Y., Hanseman, D., Curley, S.A., Cost-effectiveness of simultaneous resection and RFA versus 2-stage hepatectomy for bilobar colorectal liver metastases. J Surg Oncol 109 (2014), 516–520.
17. 17 Pawlik, T.M., Choti, M.A., Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases. Curr Oncol Rep 9 (2007), 193–201.
18. 18 Mann, C.D., Metcalfe, M.S., Leopardi, L.N., Maddern, G.J., The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg 139 (2004), 1168–1172.
19. 19 Aslanian, H.R., Burgart, L.J., Harrington, J.J., et al. Altered DNA mismatch repair expression in synchronous and metachronous colorectal cancers. Clin Gastroenterol Hepatol 6 (2008), 1385–1388.
20. 20 Nordlinger, B., Guiguet, M., Vaillant, J.C., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 77 (1996), 1254–1262.
21. 21 Margonis, G.A., Spolverato, G., Kim, Y., Karagkounis, G., Choti, M.A., Pawlik, T.M., Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases. Ann Surg Oncol 22 (2015), 4158–4165.
22. 22 Fong, Y., Fortner, J., Sun, R.L., Brennan, M.F., Blumgart, L.H., Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 (1999), 309–318 discussion 318-21.
23. 23 Pawlik, T.M., Izzo, F., Cohen, D.S., Morris, J.S., Curley, S.A., Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 10 (2003), 1059–1069.
24. 24 Cremolini, C., Loupakis, F., Antoniotti, C., et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol 26 (2015), 1188–1194.
25. 25 Sakamoto, Y., Miyamoto, Y., Beppu, T., et al. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy. Anticancer Res 35 (2015), 2359–2368.
26. 26 Huh, J.W., Park, Y.A., Jung, E.J., Lee, K.Y., Sohn, S.K., Accuracy of endorectal ultrasonography and computed tomography for restaging rectal cancer after preoperative chemoradiation. J Am Coll Surg 207 (2008), 7–12.
27. 27 Shin, S.S., Jeong, Y.Y., Min, J.J., Kim, H.R., Chung, T.W., Kang, H.K., Preoperative staging of colorectal cancer: CT vs. integrated FDG PET/CT. Abdom Imaging 33 (2008), 270–277.
28. 28 Lambregts, D.M., Beets, G.L., Maas, M., et al. Accuracy of gadofosveset-enhanced MRI for nodal staging and restaging in rectal cancer. Ann Surg 253 (2011), 539–545.
29. 29 Vauthey, J.N., Zimmitti, G., Kopetz, S.E., et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 258 (2013), 619–626 discussion 626-7.
30. 30 Van Cutsem, E., Köhne, C.H., Hitre, E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 (2009), 1408–1417.
31. 31 Heinemann, V., von Weikersthal, L.F., Decker, T., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15 (2014), 1065–1075.
32. 32 Goldberg, R.M., Sargent, D.J., Morton, R.F., et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 24 (2006), 3347–3353.